PR Newswire (May 7, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
572 people get CPHD articles and Market Currents by email alert.
Get email alerts on CPHD »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 18, 2013)
-
PR Newswire (Apr 4, 2013)
-
-
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 24, 2013)
-
PR Newswire (Jan 15, 2013)
-
PR Newswire (Jan 8, 2013)
-
-
PR Newswire (Nov 28, 2012)
-
PR Newswire (Nov 5, 2012)
-
PR Newswire (Oct 25, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
Cepheid: Awesome Company, But OverpricedDave Westenberg • Fri, Aug 10, 2012
-
-
-
Cepheid’s TB Test Looks PromisingZacks Investment Research • Mon, Sep 6, 2010 -
Cepheid Gets FDA Approval for Staph TestZacks Investment Research • Wed, Jun 9, 2010
-
Cepheid Should Benefit from New H1N1 TestZacks Investment Research • Thu, Jan 7, 2010
-
Cepheid Narrows Loss in Q3Zacks Investment Research • Mon, Nov 30, 2009
-
Cepheid: Stock Plunge Presents Buy OpportunityDouglas Cress • Tue, Jul 29, 2008 -
Cepheid Takes Hit on False MRSA Testing ClaimMichael Shulman • Wed, Mar 12, 2008 -
-
Can Cepheid Power Past $25?Marlowe Cassetti • Wed, Dec 19, 2007
-
-
FDA Approves Cepheid’s Test For Infectious BacteriaSara Calabro • Mon, Apr 23, 2007
-
-
-
-
-
Earnings Analysis For Pall Corp.: Sustainable Returns Relative To PeersCapitalCube • Fri, Sep 14, 2012 -
3 Highly Liquid Mid Caps With Strong Growth ProjectionsZetaKap • Thu, Sep 6, 2012 -
-
-
6 Liquid And High Growth Tech StocksZetaKap • Fri, Aug 10, 2012
-
-
-
-
-
-
-
6 Growing Mid-Cap Stocks With Strong LiquidityZetaKap • Wed, May 9, 2012
-
-
Hologic Must Make The Third Time A CharmStephen Simpson • Tue, May 1, 2012
-
6 Highly Shorted Tech Stocks Undervalued By EPS TrendsKapitall • Tue, Mar 20, 2012 -
-
CEPHEID's CEO Discusses Q3 2012 Results - Earnings Call TranscriptFri, Oct 19, 2012
-
Cepheid Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 19, 2012
-
Cepheid Q1 2009 Earnings Call TranscriptThu, Apr 23, 2009
-
Cepheid, Q4 2008 Earnings Call TranscriptThu, Feb 5, 2009
-
Cepheid F3Q08 (Qtr End 09/30/08) Earnings Call TranscriptTue, Oct 28, 2008
-
Cepheid Second Quarter 2008 Earnings Call TranscriptThu, Jul 24, 2008
-
Cepheid Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 1, 2013)
-
at MarketWatch.com (Apr 19, 2013)
-
PR Newswire (Apr 18, 2013)
-
PR Newswire (Apr 4, 2013)
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 24, 2013)
-
PR Newswire (Jan 15, 2013)
-
PR Newswire (Jan 8, 2013)
-
at MarketWatch.com (Dec 27, 2012)
-
PR Newswire (Nov 28, 2012)
-
PR Newswire (Nov 5, 2012)
-
PR Newswire (Oct 25, 2012)
-
PR Newswire (Oct 18, 2012)
-
at MarketWatch.com (Sep 27, 2012)
-
at CNBC.com (Sep 27, 2012)
-
at CNBC.com (Sep 26, 2012)
CPHD vs. ETF Alternatives
Company Description
Currently, there's no company description for CPHD.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, April 18, 5:53 PM
After-hours top gainers, as of 5:15 p.m.: RH +8%. IMRS +6%. BGS +5%. CPHD +5%. PRLB +5%.
After-hours top losers: AIRM -15%. CIE -6%. LSCC -5%. AMD -5%. TAHO -4%. Comment! [On the Move] - Thursday, April 18, 4:36 PM More on Cepheid (CPHD): Q1 beats on both EPS and revenue as total sales jump 19% Y/Y, driven by broader test menu utilization by our installed base and by new customer adoption. For FY13 the company sees an EPS loss of between $0.05 - $0.02, on sales of $375M to $385M, bracketing Street estimates. Comment! [Healthcare, Earnings]
- Thursday, April 18, 4:15 PM Cepheid (CPHD): Q1 EPS of $0.11 beats by $0.01. Revenue of $91.9M (+19% Y/Y) beats by $2.78M. (PR) Comment! [Earnings, Breaking News, Tech]
- Thursday, April 18, 12:10 AM Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT Comment! [Earnings]
- Wednesday, April 17, 5:35 PM Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT Comment! [Earnings]
-
Thursday, January 24, 5:42 PM
After-hours top gainers, as of 5:15 p.m.: TPX +18%. INFA +12%. RMD +6%. KLAC +3%. QIHU +3%.
After-hours top losers: SCSS -17%. FLEX -7%. SFL -6%. ETFC -5%. CPHD -4%. Comment! [On the Move] - Thursday, January 24, 5:09 PM More on Cepheid (CPHD) Q4 bottom line beats estimates as results were boosted by stronger sales and a $5.4M year-earlier charge related to the termination of a patent license. The company issues a downbeat outlook going forward however, projecting weaker-than-expected revenue for 2013. It now sees earnings of between $0.41 to $0.46 per shares on revenue of $375M to $385M. Street expectations were for $0.12 cents and $397M, respectively. Comment! [Healthcare, Earnings]
- Thursday, January 24, 4:14 PM Cepheid (CPHD): Q4 EPS of $0.2 beats by $0.09. Revenue of $92.4M. (PR) Comment! [Earnings, Breaking News, Tech]
- Thursday, January 24, 12:10 AM Notable earnings after Thursday’s close: CPHD, CRUS, ED, EGHT, ETFC, FLEX, INFA, JBHT, JNPR, KLAC, MSFT, MXIM, QLGC, RMBS, RMD, SBUX, SCSS, SXL, SYNA, T, TKR, TPX, VRSN 1 Comment [Earnings]
- Wednesday, January 23, 5:35 PM Notable earnings after Thursday’s close: CPHD, CRUS, ED, EGHT, ETFC, FLEX, INFA, JBHT, JNPR, KLAC, MSFT, MXIM, QLGC, RMBS, RMD, SBUX, SCSS, SXL, SYNA, T, TKR, TPX, VRSN Comment! [Earnings]
- Tuesday, January 8, 12:42 PM Cepheid (CPHD +5.2%) ramps higher after reporting preliminary Q4 results, saying its EPS should come in just above its prior guidance of $0.10 to $0.12 a share due to a favorable revenue mix. Analysts have been expecting a $0.02 per share net loss for the quarter. Revenue is expected to be below its prior view however, driven by weaker clinical revenue from high-burden developing countries Comment! [Healthcare, On the Move, Earnings]
- Friday, January 4, 12:14 PM Cepheid (CPHD -1.8%) slips on a downgrade to Neutral at Piper Jaffray on concerns that Q4 results and its FY13 outlook could both miss expectations. The company suffered two manufacturing glitches in FY12 that impacted its ability to meet customer cartridge demand in Q3. This created a backlog and the need to put accounts on allocation as management resolved the issue. Piper thinks CPHD may have missed its end of November allocation target. The firm also cut its price target to $34 from $42. Comment! [Healthcare, On the Move]
- Friday, December 28, 2012, 12:26 PM Cepheid (CPHD +3.8%) moves up today after the company received FDA clearance for its Xpert CT/NG diagnostic test, for the rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. Comment! [Healthcare, On the Move]
- Thursday, October 18, 2012, 4:38 PM More on Cepheid (CPHD): Q3 beats on a per share basis with revenue largely in-line with estimates. Net losses were $21.3M, or -$0.32 per share, largely due to litigation settlement charges. Results were also affected by a buildup in back orders due to intermittent interruption in availability of certain plastic parts used in the production of its Xpert cartridges, which prevented the fulfillment of all test cartridge orders in the quarter. Comment! [Healthcare, Earnings]
- Thursday, October 18, 2012, 4:18 PM Cepheid (CPHD): Q3 EPS of $0.01 beats by $0.07. Revenue of $80.5M (+15% Y/Y) in-line. (PR) Comment! [Earnings, Tech]
- Thursday, October 18, 2012, 12:10 AM Notable earnings after Thursday’s close: ACTG, AMD, ASBC, BGS, CBST, CMG, COF, CPHD, ETFC, FLEX, GOOG, MSFT, NCR, PBCT, RHI, RMBS, RVBD, SNDK Comment! [Earnings]